Tofacitinib Impurity 45
|
|
Tofacitinib Impurity 45 속성
- 녹는점
- >144°C (dec.)
- 끓는 점
- 625.5±65.0 °C(Predicted)
- 밀도
- 1.39±0.1 g/cm3(Predicted)
- 저장 조건
- -20°C Freezer, Under inert atmosphere
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨, 초음파처리)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 산도 계수 (pKa)
- 6.04±0.60(Predicted)
- 색상
- 밝은 갈색에서 갈색까지
안전
Tofacitinib Impurity 45 C화학적 특성, 용도, 생산
용도
CP-690550 N-Hydroxyl is an impurity of CP-690550 (C781350), a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis.Tofacitinib Impurity 45 준비 용품 및 원자재
원자재
준비 용품
Tofacitinib Impurity 45 공급 업체
글로벌( 18)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Standardpharm Co. Ltd. | 86-714-3992388 |
overseasales1@yongstandards.com | United States | 14336 | 58 |
ANHUI WITOP BIOTECH CO., LTD | +8615255079626 |
eric@witopchemical.com | China | 23556 | 58 |
China National Standard Pharmaceutical Corporation Limited | +8615391658522 |
overseasales@yongstandards.com | China | 11927 | 58 |
ChemStrong Scientific Co.,Ltd | 0755-0755-66853366 13670046396 |
sales@chem-strong.com | China | 18018 | 56 |
Tianjin shijia biomedical technology co., LTD | 15022261580 |
tjshj1212@163.com | China | 2417 | 58 |
Jinan blalong chemical co. LTD | 2710913286@.com |
1513643261@qq.com | China | 14253 | 58 |
Nanjing wangzhixing Pharmaceutical Technology Co., Ltd | 15850510341 |
shiqingran@wzxchem.com | China | 3592 | 58 |
Cato Research Chemicals Inc. | 020-81215950 4000-868-328 |
customer@uwalab.com | United States | 10413 | 58 |
Hubei Ruinuo Pharmaceutical Technology Co., Ltd | 13165688766 |
3008058303@qq.com | China | 5000 | 58 |
Beijing Fuchen Technology Co., Ltd | 15652759959 |
623245911@qq.com | China | 462 | 58 |
Tofacitinib Impurity 45 관련 검색:
(3R,4R)-N,1,4-trimethyl-N-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidin-3-amine
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity
Tofacitinib Impurity 36
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine
7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-
1-Piperidinepropanoic acid, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, ethyl ester, (3R,4R)-
3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanaMide
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity
butyl 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoate
3-PiperidinaMine, 1-acetyl-N,4-diMethyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)- (9CI)
N-(2,6-dimethylphenyl)-2-((2,6-dimethylphenyl)amino)acetamide
(3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine
1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE DIHYDROCHLORIDE
Tofacitinib Related Compound
Tofacitinib Impurity 2